Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Robust expansion of P-PSMA-101 CAR T cells resulted in toxicity but also durable responses in patients with mCRPC. Future trials of CAR T may be informed by the results with this nonviral engineering, TSCM cell-enriched approach.
Authors
- Matthew A. Spear
- Meredith McKean (ORCID: https://orcid.org/0000-0003-0944-7418)
- A. Hussain
- Sabrina Haag (ORCID: https://orcid.org/0000-0003-3714-6268)
- Devon J. Shedlock (ORCID: https://orcid.org/0000-0003-1018-7510)
- Alan Loh Ho (ORCID: https://orcid.org/0000-0002-6885-3742)
- Andreas G. Wibmer (ORCID: https://orcid.org/0000-0003-3432-6706)
- Christopher E. Martin
- Xiao X. Wei (ORCID: https://orcid.org/0000-0001-7093-0383)
- Joanne McCaigue
- Hamid Namini
- Gerald S. Falchook (ORCID: https://orcid.org/0000-0001-9165-2191)
- Jeff Eskew
- Slovin Sf
- Julia Coronella
- Rajesh Belani (ORCID: https://orcid.org/0009-0006-7618-8435)
- June F. Mendoza
- Tanya B. Dorff
- Ann Murphy
- Xin Gao
- Rana R. McKay
- David Y. Oh
Institutions
- University of Maryland, Baltimore (US)
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Sarah Cannon Research Institute (GB)
- University of California, San Francisco (US)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Sarah Cannon (US)
- Dana-Farber Cancer Institute (US)
- Poseida Therapeutics (United States) (US)
- University of Baltimore (US)
- University of San Francisco (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3052
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00